Ligand id: 9411

Name: bimekizumab

No information available.
Summary of Clinical Use
First-in-human clinical trial was NCT02529956 which reported clinically-meaningful efficacy [2] and lead to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis. Click here to link to's list of Phase 2 bimekizumab trials.
Mechanism Of Action and Pharmacodynamic Effects
Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity [1]. Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.